medigraphic.com
ISSN 1995-9494 (Electronic)
Revista del Hospital Clínico Quirúrgico "Arnaldo Milián Castro"

2017, Number 3

Next >>

Acta Med Cent 2017; 11 (3)

Supervivencia de los pacientes con linfoma no Hodgkin difuso B de células grandes

Gómez MY, García SD, Trujillo AL

Language: Spanish
References: 20
Page: 1-12
PDF size: 241.26 Kb.


ABSTRACT

Introduction: non-Hodgkin's lymphomas are, at present, a health problem. Diffuse large B cell lymphomas represent the 80% of all cases; in Cuba constitute 30% of all patients diagnosed with lymphomas annually. Objective: to evaluate the global and free survival of the events according to the treatment received in the first line. Methods: an analytical, longitudinal and prospective study was performed in adults with diffuse large B cell lymphoma in Villa Clara between 2006 and 2015. Results: the sample consisted of 102 patients; 67,7% were male. Of the total sample, 70 patients were treated with cyclophosphamide, doxorubicin, vincristine and prednisone without rituximab, while the remainder used the monoclonal antibody as part of the therapy. Overall survival was 96,9% for those treated with rituximab and 77,1% for those who did not. Event free survival was higher in patients receiving rituximab at all time-cuts analyzed. Overall survival was lower in patients at greater risk at debut. Conclusions: patients receiving immunochemotherapy had significantly greater global and event free survival than those who used only chemotherapy.


REFERENCES

  1. Jaffe ES, Pittaluga S. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. Hematology Am Soc Hematol Educ Program [Internet]. 2011 [Citado 15 ene 2013];2011: 506-14. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22160082

  2. Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2015 [Citado 15 ene 2013];26(Suppl 5):v116-v125. Disponible en: http://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma

  3. National Comprehensive Cancer Network. Non-Hodgkin’s lymphomas. Clinical practice guidelines in oncology. NCCN Guidelines version 2 [Internet]. 2012 [Citado 15 ene 2013]. Disponible en: https://www.nccn.org/about/nhl.pdf

  4. Shankland KR, Armitage JO, Hancock BW: Non-Hodgkin lymphoma. Lancet [Internet]. 2012 Sep [Citado 15 ene 2013];380(9844): 848-57. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22835603

  5. Larouche JF. Lymphoma Recurrence 5 Years or Later Following Diffuse Large B-cell Lymphoma: Clinical Characteristics and Outcome. J Clin Oncol [Internet]. 2010 Abr [Citado 15 ene 2013];28:2094-2100. Disponible en: http://ascopubs.org/doi/full/10.1200/jco.2009.24.5860

  6. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med [Internet]. 2010 Apr 15 [Citado 15 ene 2013];362(15):1417–29. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMra0807082

  7. Staudt LM, II Therapy of DLBCL based on genomics. Hematol Oncol. 2013;31:S26–S28. doi: 10.1002/hon.2062

  8. Cultrera JL, Dalia SM. Diffuse large B-cell lymphoma: current strategies and future directions. Cancer Control [Internet]. 2012 Jul [Citado 15 ene 2013];19(3): 204-13. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22710896

  9. Perry AM, Mitrovic Z, Chan WC. Biological prognostic markers in diffuse large B-cell lymphoma. Cancer Control [Internet]. 2012 Jul [Citado 15 ene 2013];19(3):214-26. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22710897

  10. Said JW. Aggressive B-cell lymphomas: how many categories do we need? Mod Pathol [Internet]. 2013 Jan [Citado 21 Jul 2016];26 Suppl 1:S42-56. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406768/

  11. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. Who classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.

  12. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood [Internet]. 2011 May 12 [Citado 15 ene 2013];117(19): 5019-32. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/21300984

  13. Sehn LH. Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program [Internet]. 2012 [Citado 15 ene 2013];2012: 402-9. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23233611

  14. Guevara NM, Jaramillo PE, Rendón J, Gaviria LM. Caracterización de factores pronósticos al diagnóstico de pacientes con Linfoma B difuso de células grandes en un Hospital Universitario, 2009-2012. Acta Med Colomb [Internet]. 2014[Citado 15 ene 2013];39: 137-147. Disponible en: http://www.scielo.org.co/pdf/amc/v39n2/v39n2a09.pdf

  15. Coiffer B, Lepage E, Briere J, et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med [Internet]. 2002 Jun 24 [Citado 15 ene 2013];346(4) : 235-242. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/11807147

  16. Pfreundschuh M, Trumper L, Osterborg A. CHOP-like chemotherapy plus Rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large-B –cell lymphoma: a randomise controlled by the Mabthera International Trial(MinT) Group. Lancet Oncol [Internet]. 2006 May [Citado 21 jul 2016];7(5): 379-391. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/16648042

  17. Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011 Oct;12(11):1013-22 doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21.

  18. Gutiérrez-García G, Colomo L, Villamor N, Arenillas L, Martínez A, Cardesa T. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma. 2010 Jul;51(7):1225-32. doi: 10.3109/10428194.2010.483301.

  19. Persky DO, Unger JM, Spier CM. Phase 2 study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol [Internet]. 2008 may [Citado 21 Jul 2016];26(14): 2258-2263. Disponible en: http://ascopubs.org/doi/abs/10.1200/jco.2007.13.6929

  20. Cunningham D, Smith P, Mouncey P. A phase 3 trial comparing R-CHOP 14 and RCHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma (abstract). J Clin Oncol [Internet]. 2009 May [Citado 21 Jul 2016];27(15s): Abstract 8506. Disponible en: http://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.8506




2020     |     www.medigraphic.com